Investors

Investors image

News

Mar.27, 2025 Release
Shionogi Submits Supplemental New Drug Application for Ensitrelvir in Japan for the Post-Exposure Prophylaxis of COVID-19.
Mar.24, 2025 Release
Shionogi Announces Appointment of Corporate officers, the Establishment of new Organization and Personnel Reassignment (Effective April 1, Jun 18, and July 1, 2025)
Mar.24, 2025 Release
Notice of Transition to Company with Audit and Supervisory Committee and the Candidates for Directors After the Transition
Mar.13, 2025 Release
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
Mar.03, 2025 Notice
Shionogi Collaborates with RNID to Improve Communication in Healthcare Settings for Patients Who Are Deaf, Have Hearing Loss or Tinnitus
  • Latest IR Information

    ・Financial Results / Supplement

    　- Presentation material

    　- Transcript

    more
  • IR Library

    ・Financial Results / Supplement

    ・Presentation materials

    ・Annual Report / Integrated Report / EHS Report

    ・Corporate Governance Report

    ・Pipeline

    ・Fact Book

    more
  • Management Policy

    ・Philosophy

    ・Business Plan

    ・Corporate Governance

    ・Disclosure Policy

    ・Business Risks

    more
  • Shareholder Information

    ・Information on Shares

    ・General Meeting of Shareholders

    ・Analyst Coverage

    ・Bonds & Ratings

    more
  • Individual Investors

    ・Pharmaceutical Business

    ・Shionogi's Strength

    ・Business Strategy

    ・Business Activities, etc.

     

    more
  • Sustainability

    View the Shionogi's approach to sustainable growth

    more
  • Financial Highlights

    Financial highlights for the last five years

    more
  • IR Calendar

    The schedule and results of IR events in each fiscal year

     

    more